OM1 offers a data analytics platform. It predicts the outcomes of patients so that hospitals, healthcare systems, and other stakeholders can make decisions about the health condition of patients. It serves the healthcare industry. OM1 was founded in 2015 and is based in Boston, Massachusetts.
ESPs containing OM1
The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.
The real-world data market offers a variety of value propositions to the pharmaceutical industry, drug labs, and healthcare organizations. It provides access to diverse patient populations, longitudinal real-world data, and patient-powered or EHR-powered controls that can replicate real-world scenarios. This can help shorten drug development timelines, reduce patient recruitment burdens and costs,…
Research containing OM1
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned OM1 in 2 CB Insights research briefs, most recently on Dec 12, 2022.
Expert Collections containing OM1
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
OM1 is included in 4 Expert Collections, including Artificial Intelligence.
Companies developing artificial intelligence solutions, including cross-industry applications, industry-specific products, and AI infrastructure solutions.
Value-Based Care & Population Health
The VBC & Population Health collection includes companies that enable and deliver care models that address the health needs for defining populations along the continuum of care, including in the community setting, through participation, engagement, and targeted interventions.
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Precision Medicine Tech Market Map
This CB Insights Tech Market Map highlights 160 precision medicine companies that are addressing 9 distinct technology priorities that pharmaceutical companies and healthcare providers face.
OM1 has filed 6 patents.
Latest OM1 News
Nov 29, 2023
High TMB Linked to Better Outcomes of ICI Therapy in Gastric Cancer Patients with a high tumor mutational burden had significantly longer progression-free survival and overall survival. Source: Getty Images Patients with gastric cancer have better outcomes of immune checkpoint inhibitor (ICI) treatment if they have a high tumor mutational burden (TMB), according to a meta-analysis published in International Immunopharmacology. Researchers found that overall survival (OS) and progression-free survival (PFS) were longer in patients with a high TMB, and these benefits were drive by Asian patients. This meta-analysis included 11 retrospective studies of patients with gastric or gastroesophageal cancer treated with ICIs. Nine studies were conducted in Asian countries and 2 in non-Asian countries. Continue Reading Patients received combination treatment in 6 studies and ICI monotherapy in 5 studies. The ICIs included nivolumab, pembrolizumab, atezolizumab, tislelizumab, and toripalimab. Using data from 8 studies, the researchers found that patients with a high TMB had significantly longer OS than patients with a low TMB (hazard ratio [HR], 0.65; 95% CI, 0.55-0.77; P <.001). Using data from 10 studies, the researchers found that patients with a high TMB had significantly longer PFS than patients with a low TMB (HR, 0.51; 95% CI, 0.33-0.77; P =.001). A subgroup analysis revealed that the OS benefit was significant in Asian patients with a high TMB (HR, 0.56; 95% CI, 0.43-0.72; P <.001) but not in non-Asian patients with a high TMB (HR, 0.61; 95% CI, 0.32-1.16; P =.133). Similarly, the PFS benefit was significant in Asian patients with a high TMB (HR, 0.45; 95% CI, 0.28-0.72; P =.001) but not in non-Asian patients with a high TMB (HR, 0.68; 95% CI, 0.31-1.48; P =.322). The OS in high-TMB patients was similar whether they received combination therapy or monotherapy. The PFS benefit, on the other hand, was significant in high-TMB patients who received monotherapy (HR, 0.39; 95% CI, 0.22-0.67; P =.001) but not in those who received combination therapy (HR, 0.84; 95% CI, 0.65-1.08; P =.192). “This meta-analysis demonstrated that gastric cancer patients with high TMB showed significant benefits from ICIs compared to … low TMB patients, particularly in Asian populations,” the researchers wrote. “In the future, there is a requirement for a large number of RCTs [randomized clinical trials] to prove that TMB is a feasible predictor for prognosis of gastric cancer patients treated with ICIs.” Reference
OM1 Frequently Asked Questions (FAQ)
When was OM1 founded?
OM1 was founded in 2015.
Where is OM1's headquarters?
OM1's headquarters is located at 31 Street James Avenue, Boston.
What is OM1's latest funding round?
OM1's latest funding round is Series D.
How much did OM1 raise?
OM1 raised a total of $176.25M.
Who are the investors of OM1?
Investors of OM1 include General Catalyst, Polaris Partners, Scale Venture Partners, Flare Capital Partners, 7wire Ventures and 4 more.
Who are OM1's competitors?
Competitors of OM1 include Holmusk and 3 more.
Compare OM1 to Competitors
Aetion operates as a healthcare analytics company. It provides decision-grade real-world evidence solutions to biopharma companies, payers, and regulatory agencies. It offers a platform that analyzes data from the real world to produce scientifically validated answers on treatments, effectiveness, and value. The company was founded in 2012 and is based in New York, New York.
Verana Health operates as a digital health company. It provides a drug lifecycle, medical practice, and medical society insights platform to accelerate medical research for patients. The company was founded in 2018 and is based in San Francisco, California.
ConcertAI is a healthcare technology company. It uses artificial intelligence (AI) to help oncologists make more informed treatment decisions for their patients. The platform analyzes large datasets of clinical and genomic data to identify patterns and insights which is used for personalized cancer treatment. It was formerly known as Precision HealthAI. It was founded in 2017 and is based in Cambridge, Massachusetts.
Komodo Health operates as a healthcare data-insights platform. It brings transparency and market intelligence to the healthcare sector. It offers services to deliver innovative therapies, patient advocacy, cost management of healthcare bills, and medical requirements for practitioners. The company was founded in 2014 and is based in San Francisco, California.
Promptly Health is a global provider of end-to-end Real World Evidence solutions in the healthcare sector. The company's main services include the generation of new knowledge from harmonized clinical, socio-economic, and claims data, augmented with the collection of longitudinal patient-reported data and patient-generated digital biomarkers. Promptly Health primarily sells to the life sciences sector, healthcare providers, and healthcare payers. It was founded in 2017 and is based in Porto, Portugal.
Owkin specializes in developing artificial intelligence (AI) technologies for clinical research and developing drugs and treatments for patients. It empowers researchers in hospitals, universities, and the biopharmaceutical industry to understand drug efficacy varies, improves the drug development process, and help identify key drugs and treatments for individual patients to improve patient outcomes. The company was founded in 2016 and is based in New York, New York.